Opdivo Misses Disease-Free Survival Goal in Kidney Cancer Trial
Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914.
Opdivo-Chemo Combination Improves Survival in GI Cancers
Treatment with Opdivo and chemotherapy improved survival in patients with gastrointestinal cancers, compared with chemotherapy alone, according to a phase 3 trial.
Yescarta Improves Survival for Patients With Large B-Cell Lymphoma
Data from the ZUMA-7 trial shows that age alone should not be a barrier of consideration of administering CAR-T cell therapy to patients with large B-cell lymphoma, says Dr. Marie José Kersten.
2 Commerce Drive Cranbury, NJ 08512